Home / Flashcard library / Health & emergency services / PTCB PTCE / NAPLEX

Health & emergency services

PTCB PTCE / NAPLEX flashcards

13 decks · 1,015 cards · built into Willys · free samples below

Get the app Study a free sample

Written against: Top-drug lists and federal pharmacy law as of 2026; PTCE content outline effective 6 January 2026. Updated 2026-10-10.

What's in it

Every deck follows the course outline, with tags you can study or suspend topic by topic. Open a deck to study its free sample right here.

Learn · 8 decks · 645 cards

Concepts, mechanisms and the questions a course or exam asks about them.

Top Drugs: Brand ↔ Generic, Part 1 Brand to generic name and drug class for the most-prescribed US cardiovascular, lipid, anticoagulant and diabetes drugs, each with one hallmark warning or counseling point, plus ISMP look-alike name pairs. 10 free · 84 cards in the app Top Drugs: Brand ↔ Generic, Part 2 Brand to generic name and drug class for top US psychiatric, neurologic, pain, respiratory, GI, anti-infective, endocrine and urology drugs, each with one hallmark warning or counseling point, plus ISMP look-alike name pairs. 10 free · 84 cards in the app Interactions, Adverse Effects & Counseling Classic drug interactions (warfarin, CYP450 and P-gp, serotonergic, QT, renal and absorption), hallmark adverse effects, must-say counseling points for patches, sprays, insulin, iron and the pill, narrow-therapeutic-index drugs and Beers Criteria concepts, mostly as applied cases. 10 free · 77 cards in the app Cardiovascular and Renal Hypertension (including emergencies and pregnancy), HFrEF guideline classes, anticoagulants, reversal agents and antiplatelets, antiarrhythmic toxicities, lipid agents, antianginals, diuretics, potassium binders and drug choices in CKD — mechanisms, risks and counseling, with no doses. 10 free · 80 cards in the app Endocrine and GI Diabetes classes and cardiorenal choice, insulin, DKA and hypoglycemia rescue, thyroid, adrenal and bone drugs, hormone therapy, emergency contraception and testosterone, acid suppression, H. pylori, IBD, nausea, laxatives and antidiarrheals, and hepatic drug use — with no doses. 10 free · 80 cards in the app Pulmonary, Oncology and Immunology Asthma, COPD and pulmonary hypertension therapy, inhaler technique, chemotherapy toxicities and protectants, antiemetics and supportive care, targeted and immune therapies, transplant drugs, biologic infection screening, gout, anaphylaxis and vaccines — with no doses. 10 free · 80 cards in the app Infectious Disease Antibacterial spectra, toxicities and interactions, C. difficile, empiric UTI, pneumonia, meningitis and neutropenic fever, dental prophylaxis, STIs and doxy-PEP, antifungals, antivirals, HIV treatment and PrEP, and TB drug toxicities — with no doses. 10 free · 80 cards in the app CNS, Psychiatry and Pain Antiepileptics and status epilepticus, Parkinson and Alzheimer drugs, migraine, antidepressants and serotonin toxicity, antipsychotics with NMS, tardive dyskinesia and metabolic risk, lithium, ADHD, sleep drugs, alcohol and opioid use disorder, opioid safety and analgesic toxicity — with no doses. 10 free · 80 cards in the app

Drills · 1 deck · 80 cards

Short answers and cloze blanks for the facts you simply have to know cold.

Cloze: Top Drugs & Counseling Fill-in-the-blank drills on top-prescribed brand and generic names, boxed warnings, and the counseling timing facts patients ask about, one fact per blank and no doses. 8 free · 80 cards in the app

Practice · 4 decks · 290 questions

Multiple-choice practice questions, one best answer each, with the reasoning.

PTCB Practice: Sig Codes, Law & Safety Sig codes and error-prone abbreviations, controlled-substance rules, DEA forms and disposal, look-alike names and error prevention, USP compounding with garbing, hoods and hazardous drugs, NDCs, recalls, Orange and Purple Books, HIPAA, OBRA '90, REMS, calculations and storage. 6 free · 80 questions in the app Practice Questions: PTCB & Top Drugs Multiple-choice practice questions, one best answer each, on sig codes, federal pharmacy law and safety, storage, top-drug brand and generic names and classes, key interactions and counseling. 6 free · 70 questions in the app Practice Questions, Part 1 Multiple-choice practice questions, one best answer each, on cardiovascular and renal drugs, diabetes, thyroid, GI and liver, asthma and COPD, oncology, transplant and biologics. 6 free · 70 questions in the app Practice Questions, Part 2 Multiple-choice practice questions, one best answer each, on antimicrobials, antivirals, HIV and TB drugs, antiepileptics, Parkinson and psychiatric drugs, and opioid and analgesic safety. 6 free · 70 questions in the app

Cloze decks have one or more blanks per sentence; the app makes one card per blank.

Study guide

Topics covered

The decks follow the order of the course outline. Numbers are cards per topic.

  • Lipids 23
  • ACE Inhibitors & ARBs 22
  • Calcium Channel Blockers 4
  • Beta Blockers 9
  • Diuretics 6
  • Other Cardiovascular 8
  • Anticoagulants & Antiplatelets 23
  • Diabetes 34
    • Oral Agents 18
    • Injectables & Insulins 16
  • Antidepressants 20
  • Antipsychotics & Mood Stabilizers 8
  • Anxiety · Sleep & ADHD 11
  • Neurology 55
    • Antiepileptics 15
    • Parkinson Disease 7
    • Alzheimer Disease 4
    • Migraine 4
  • Pain · Muscle & Gout 11
  • Respiratory & Allergy 13
  • Gastrointestinal 43
    • GERD and Peptic Ulcer 7
    • Helicobacter pylori 4
    • Inflammatory Bowel Disease 5
    • Hepatic Considerations 7
    • Nausea Constipation and Diarrhea 3
  • Anti-infectives 22
  • Endocrine · Thyroid & Bone 13
  • Urology & Sexual Health 10
  • Other Top Drugs 2
  • Warfarin Interactions 10
  • CYP450 Interactions 15
  • Serotonergic & MAOI Interactions 9
  • QT Prolongation 4
  • Pharmacodynamic & Renal Interactions 12
  • Absorption & Chelation 8
  • Hallmark Adverse Effects 9
  • Counseling Points 20
  • Narrow Therapeutic Index 4
  • Older Adults & Beers Criteria 7
  • Sig Codes 13
  • Error-Prone Abbreviations 7
  • Controlled Substances 21
  • DEA Forms & Records 12
  • Medication Safety 15
  • Compounding Standards 9
  • NDC · Recalls & FDA 9
  • Privacy & Pharmacy Law 7
  • REMS 5
  • Calculations 11
  • Storage 6
  • Cardiovascular 86
    • Hypertension 11
    • Heart Failure 10
    • Anticoagulants 14
    • Antiplatelets 6
    • Antiarrhythmics 12
    • Lipids 8
    • Ischemic Heart Disease 3
  • Renal 22
    • Diuretics 7
    • Chronic Kidney Disease 9
  • Endocrine 71
    • Noninsulin Diabetes Agents 23
    • Insulin 7
    • Thyroid 9
    • Adrenal and Corticosteroids 5
    • Osteoporosis 7
    • Reproductive Health 3
  • Pulmonary 30
    • Asthma 11
    • COPD and Smoking Cessation 6
    • Inhaler Technique 5
    • Pulmonary Arterial Hypertension 2
  • Oncology 33
    • Chemotherapy Toxicities 12
    • Supportive Care 5
    • Targeted Hormonal and Immunotherapy 10
  • Immunology 35
    • Transplant Immunosuppressants 7
    • Conventional DMARDs 2
    • Biologics and Infection Risk 7
    • Vaccines 8
    • Gout 3
    • Allergy and Anaphylaxis 2
  • Infectious Disease 116
    • Beta-Lactams 11
    • Gram-Positive Agents 7
    • Aminoglycosides Macrolides and Tetracyclines 7
    • Fluoroquinolones and Other Antibacterials 7
    • Clostridioides difficile 4
    • Empiric Therapy 6
    • Antifungals 8
    • Antivirals 10
    • HIV 11
    • Tuberculosis 6
    • Sexually Transmitted Infections 3
  • Psychiatry 50
    • Antidepressants 11
    • Antipsychotics 10
    • Bipolar Disorder and Lithium 5
    • ADHD 4
    • Anxiety and Insomnia 3
    • Substance Use Disorders 2
  • Pain 22
    • Opioids 7
    • NSAIDs and Acetaminophen 8

A study plan

  • 37 new cards a day covers everything in a month, leaving the last weeks for review.
  • 19 new cards a day covers everything in two months, leaving the last weeks for review.
  • 13 new cards a day covers everything in three months, leaving the last weeks for review.

Willys schedules reviews for you (FSRS spaced repetition), so the daily number above is only for new cards; reviews of what you have learned come back on their own. Study a topic's cards right after you meet it in class, suspend topics you have not reached yet, and use the app's quiz mode in the final two weeks.

How to get these decks

  1. Install Willys on your iPhone, iPad or Mac — App Store. 14-day free trial, then $14.99 a year.
  2. In Willys, tap Exam Library at the top of your Decks (or Browse Exam Library… under the + button), find the exam on its shelf or by search, tick it and tap Add.
  3. Study. The exam comes in as its own collapsible folder, every card scheduled by FSRS spaced repetition. Nothing you already have is changed.

Every deck is built into Willys

All 13 PTCB PTCE / NAPLEX decks (1,015 cards), with FSRS spaced repetition, quizzes and mock tests, on iPhone, iPad and Mac. 14-day free trial, then $14.99 a year.

Get the app

In Willys, tap Exam Library at the top of your Decks (or Browse Exam Library… under the + button), find the exam on its shelf or by search, tick it and tap Add.

About these cards

Review status: Second-reader reviewed, with corrections applied.

Checked against:

  • Checked against FDA prescribing information on DailyMed (US National Library of Medicine; public domain); reference only, no label text copied.
  • Drug selection informed by publicly reported US top-prescribed drug rankings (ClinCalc DrugStats, based on MEPS data); reference only.
  • Look-alike name pairs cross-checked against the ISMP List of Confused Drug Names; reference only.
  • US brand market status checked against the FDA Orange Book discontinued drug product list (US Food and Drug Administration; public domain); reference only.
  • NAPLEX® is a registered trademark of the National Association of Boards of Pharmacy (NABP), and PTCB is a trademark of the Pharmacy Technician Certification Board; neither is affiliated with or endorses this product.
  • Brand market status (discontinued-brand notes) checked against FDA Orange Book data, FDA Federal Register notices and Drugs.com brand-status listings; reference only.
  • Checked against FDA prescribing information on DailyMed (US National Library of Medicine; public domain) and the FDA Drug Development and Drug Interactions table of substrates, inhibitors and inducers; reference only, no text copied.
  • Older-adult items checked against the American Geriatrics Society 2023 Updated Beers Criteria (reference only); disposal guidance against FDA's drug-disposal pages (take-back first, then the flush list; public domain).
  • Missed-pill and backup rules checked against the CDC US Selected Practice Recommendations for Contraceptive Use (2024); triptan–SSRI evidence against the American Headache Society position statement (reference only; no text copied).
  • Torsades de pointes treatment checked against the 2025 American Heart Association Guidelines for CPR and ECC, Part 9: Adult Advanced Life Support; reference only, no text copied.
  • Checked against FDA prescribing information and patient labeling on DailyMed (US National Library of Medicine; public domain); reference only, no label text copied.
  • Brand market status (discontinued-brand notes) checked against FDA Orange Book data via mirrors, FDA Federal Register notices and Drugs.com brand-status listings; reference only.
  • Drug selection informed by publicly reported US top-prescribed drug rankings (ClinCalc DrugStats, based on MEPS data); nitroglycerin counseling against current ACC/AHA chest-pain guidance; reference only.
  • Checked against the Controlled Substances Act and 21 CFR Part 1300 series and the DEA Pharmacist's Manual (US government; public domain); reference only, no text copied.
  • Abbreviation and look-alike items checked against The Joint Commission Do Not Use list and ISMP's error-prone abbreviation, confused drug name and high-alert medication lists; reference only.
  • Recall classes, NDC structure and Orange Book codes checked against FDA web pages (public domain); USP chapter scopes and storage definitions checked against USP General Notices (reference only).
  • USP chapters 795 (2023 revision), 797 and 800 checked against USP and NABP summaries; EPA RCRA Subpart P (2019), DEA disposal and partial-fill rules (21 CFR Parts 1306 and 1317), and FDA disposal guidance and Purple Book web pages (reference only; no text copied).
  • Pseudoephedrine sale rules checked against DEA Diversion's Combat Methamphetamine Epidemic Act pages, child-resistant packaging against 16 CFR 1700.14 (Poison Prevention Packaging Act), the NDC format against FDA's 2026 final rule (91 FR 10749), and iPLEDGE against FDA's iPLEDGE REMS page (US government; public domain; reference only).
  • HIPAA items checked against 45 CFR Parts 160 and 164, OBRA '90 against 42 U.S.C. 1396r-8(g), and biosimilar interchangeability against 42 U.S.C. 262 (US government; public domain); reference only.
  • Law items checked against the Controlled Substances Act and 21 CFR Part 1300 series and the DEA Pharmacist's Manual, recall classes against 21 CFR 7.3, child-resistant packaging against 16 CFR 1700, privacy against the HIPAA rules (45 CFR Parts 160 and 164) and counseling duties against OBRA '90 (US government; public domain); abbreviation and look-alike items against The Joint Commission Do Not Use list and ISMP's error-prone abbreviation and confused drug name lists; reference only, no text copied.
  • Recall classes, NDC structure (including FDA's 2026 final rule on the 12-digit format) and Orange Book codes checked against FDA web pages and the Federal Register (public domain); USP chapter scopes and storage definitions against USP General Notices; drug names, classes, interactions and counseling points against FDA prescribing information on DailyMed (US National Library of Medicine; public domain) and the FDA table of CYP substrates, inhibitors and inducers; reference only.
  • NABP NAPLEX competency statements (topic outline only; no text copied)
  • Checked against FDA prescribing information and standard pharmacotherapy references (reference only; no text copied)
  • Checked against the AHA/ACC hypertension guidelines (2017 and 2025), the 2022 AHA/ACC/HFSA heart failure guideline, the KDIGO 2024 CKD guideline, ACOG guidance on chronic hypertension in pregnancy, and the FDA notice of andexanet alfa's December 2025 US withdrawal (reference only; no text copied)
  • Checked against the ADA Standards of Care in Diabetes—2026, the ACG 2024 clinical guideline on treatment of Helicobacter pylori infection, the ATA 2016 hyperthyroidism guidelines, the ATA 2026 guidelines for thyroid disease in preconception, pregnancy and postpartum, ACOG guidance on nausea and vomiting of pregnancy, the CDC US Selected Practice Recommendations for Contraceptive Use (2024), the FDA's January 2024 safety communication on denosumab and severe hypocalcemia, and the FDA's November 2025 announcement on menopausal hormone therapy labeling (reference only; no text copied)
  • Also checked against the FDA Orange Book and drug shortage database, the Baveno VII portal hypertension consensus (2022), and the CPIC thiopurine dosing guideline (2025 update) (reference only; no text copied)
  • Checked against the GINA 2025 report and its 2026 update, the GOLD 2026 report, the 2020 ACR gout guideline, the FDA's 2025 notices on endothelin receptor antagonist REMS, the FDA's 2025–2026 capecitabine and fluorouracil labeling on DPD deficiency, ACR guidance on TB screening before biologics, and AAAAI/ACAAI anaphylaxis practice parameters (reference only; no text copied)
  • Checked against the IDSA/SHEA C. difficile guideline (2021 focused update), the ATS/IDSA community-acquired pneumonia guideline (2019) and its ATS update (2025), the IDSA/ESCMID uncomplicated cystitis and pyelonephritis guideline (2010), the AAAAI/ACAAI drug allergy practice parameter (2022), the ASHP/IDSA/PIDS/SIDP vancomycin monitoring consensus (2020), CDC STI Treatment Guidelines (2021) and doxy-PEP recommendations (2024), CDC PrEP guidance, the 2021 AHA scientific statement on endocarditis prophylaxis, and ATS/CDC/IDSA tuberculosis treatment guidance (reference only; no text copied)
  • Neutropenic fever example checked against the IDSA 2010 fever and neutropenia guideline as summarized in a 2019 US book chapter (Baluch and Shewayish, "Neutropenic Fever", in Velez et al., eds, Infections in Neutropenic Cancer Patients; PMC7120136), the ASCO/IDSA 2018 outpatient fever and neutropenia guideline, and the eviQ (Cancer Institute NSW) neutropenic fever protocol (reference only; no text copied).
  • Checked against the American Epilepsy Society 2016 guideline on convulsive status epilepticus, the 2026 AAN/AHS guideline on pharmacologic migraine prevention in adults, the 2004 ADA/APA consensus on antipsychotics and metabolic monitoring, and SAMHSA guidance on medications for opioid and alcohol use disorder (reference only; no text copied)
  • Guidelines checked against (reference only; no text copied): 2025 AHA/ACC hypertension guideline; 2022 AHA/ACC/HFSA heart failure guideline; GINA 2025 report and 2026 update; GOLD 2026 report; ACG 2024 H. pylori guideline; AGS 2023 Beers Criteria
  • Also checked against (reference only; no text copied): ADA Standards of Care in Diabetes 2026; ASH 2018 guideline on VTE in pregnancy; ASCO guideline on immune-related adverse events; ATA 2016 hyperthyroidism guideline; CPIC thiopurine guideline (2025 update); CDC guidance on vaccinating pregnant persons

These are independent study notes written for Willys. They are not official exam material, may contain mistakes, and are no substitute for your course, your teacher or the exam owner's own publications. Found an error? Tell us — corrections ship as a new version of the deck.

Not clinical guidance. These cards prepare you for an exam. Never use them to make decisions about a patient's care: follow current guidelines, prescribing information and your institution's policies. The decks contain no doses.

Use of these pages is covered by our Terms of Use.